
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly demonstrates strong growth potential supported by significant revenue increases across its key therapeutic areas, notably cardiometabolic solutions where revenues surged by 16.1% year-over-year in Q4. The electrophysiology segment also exhibited remarkable growth, achieving a 35% year-over-year increase, which aligns with industry forecasts of approximately 15% growth in the EP market through 2026. Furthermore, with neuromodulation revenues rising by 10% year-over-year, Eli Lilly's diverse product offerings and consistent market expansion underscore a favorable outlook for the company's financial performance.
Bears say
Eli Lilly's stock outlook is negatively impacted by a significant 18% decline in share price following a disappointing guidance for 2026 and underperformance in its electrophysiology (EP) segment that fell short of consensus expectations. The company's reliance on the favorable outcomes of the upcoming CHAMPION-AF study, along with potential slow uptake of its portfolio and high debt levels due to recent acquisitions, raises concerns about operational leverage and financial stability. Additionally, risks such as pricing pressures and disappointing performance of key products like tirzepatide further contribute to an uncertain and concerning financial outlook for Eli Lilly.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares